Christopher Acevedo
About Christopher Acevedo
Christopher P. Acevedo is the Chief Financial Officer of OS Therapies (OSTX), serving on a part‑time basis since July 2023; he is 62 years old and holds an MBA and a BS in Accounting from the University of Delaware, and CPA certificates in Delaware, Maryland, and Pennsylvania . Under his employment letter, he is contracted for approximately 12 hours per month, at-will, at $3,000 per monthly pay period, with eligibility for a discretionary performance bonus up to 50% of base salary; he also received 200,000 shares for past service and an option grant for 100,000 shares at a $0.001 exercise price effective March 31, 2023 . As a public-company officer, he provides SOX 302/906 certifications alongside the CEO, reflecting responsibility for disclosure controls and internal control over financial reporting . As of 2024, the company disclosed no explicit TSR, revenue, EBITDA or similar performance metrics tied to named executive officer pay and, as an EGC, is not required to conduct a say‑on‑pay vote .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| OS Therapies (OSTX) | Chief Financial Officer (part-time) | July 2023–present | Principal financial and accounting officer; signs SOX certifications for 10-Qs |
| Shore Accountants MD Inc. (owned by Acevedo) | Owner/Operator (CPA firm) | 2010–present | Provides payroll, bookkeeping, and tax services; OSTX engaged firm (related‑party) |
External Roles
| Organization | Role | Years | Scope |
|---|---|---|---|
| Certified public accounting firm with offices in DE and MD (Shore Accountants MD Inc.) | Owner/Operator; CPA | 2010–present | Serves small/mid-sized businesses; performed payroll, bookkeeping, and tax preparation for OSTX |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | $36,000 | $36,000 |
| Target Bonus % | Up to 50% of base (per employment letter) | Up to 50% of base (per employment letter) |
| Actual Bonus Paid ($) | $0 | $0 |
Performance Compensation
Stock Options
| Grant/Year | Number of Options | Exercise Price | Vesting Schedule | Expiration | Grant Date/Fair Value | Status/Notes |
|---|---|---|---|---|---|---|
| 3/31/2023 grant (per employment letter) | 100,000 | $0.001 | Company disclosed executive ISO options vest over 3 years | — | — | Options for executive officers had not vested and had a fair value of $0 as of 12/31/2024 |
| 2024 option awards (SCT) | — | — | 3‑year vesting for executive ISO options | — | $122,523 (aggregate grant date fair value) | Included in SCT for 2024; details by grant not specified beyond ISO/vesting |
Stock/Share Awards
| Award | Grant/Earned Date | Shares | Fair Value | Vesting/Trigger | Notes |
|---|---|---|---|---|---|
| Past service equity grant (employment letter) | 1/1/2023 | 200,000 | — | Not specified | Granted for prior service; at-will, part‑time CFO |
| Make‑whole shares (officer/director program) | Earned upon IPO; issued Oct 2024 | 9,375 | $37,500 | Earned upon successful IPO | Company stated all make‑whole shares due to officers/directors issued Oct 2024 |
Performance Plan Details
- Disclosed incentive plan metrics/weights for NEOs were not specified for 2023–2024; bonus eligibility is discretionary up to 50% of base per employment letter .
Equity Ownership & Alignment
| As of | Beneficially Owned Common Shares | % of Common Outstanding | Series A Preferred Owned | Shares Outstanding (context) | Pledging/Hedging Policy |
|---|---|---|---|---|---|
| Aug 20, 2025 | 109,375 | <1% | 0 | 31,645,015 common; 567,500 Series A outstanding | No formal hedging/insider trading policy adopted yet; board intends to adopt in 2025 |
Notes:
- Beneficial ownership includes securities exercisable/convertible within 60 days; the table shows Acevedo with <1% ownership .
- No disclosure of pledged shares for Acevedo in the proxy; no formal anti‑hedging policy was in place as of the filing .
Employment Terms
| Term | Detail |
|---|---|
| Employment basis | At‑will; part‑time (12 hours/month on average) |
| Base pay | $3,000 per monthly pay period (employment letter) |
| Bonus eligibility | Up to 50% of base salary (discretionary, based on personal and company performance, subject to board approval) |
| Equity | 200,000 common shares for past service; option to purchase 100,000 shares at $0.001 effective 3/31/2023 |
| Severance (termination without Cause / resignation for Good Reason) | Continuation of base salary for 12 months and a prorated bonus payment equivalent to 35% of annualized base salary |
| Change‑of‑control | Employment letter has no change‑of‑control provisions |
| Restrictive covenants | Invention & non‑disclosure; non‑compete during employment and for one year thereafter; non‑solicit for one year post‑employment |
Compensation Committee Analysis
- Compensation Committee members: Theodore F. Search, Pharm.D. (Chair), Olivier R. Jarry, John Ciccio; all determined independent under NYSE rules; committee held two meetings in 2024 .
- Committee responsibilities include setting/approving Section 16 officer compensation, overseeing plans, and retaining compensation advisors under independence standards .
Related-Party Transactions (Governance)
- OSTX engaged Shore Accountants MD Inc., 100% owned by Acevedo, for payroll/bookkeeping/tax; accounts payable owed to Shore Accountants MD Inc. were $26,765 at 12/31/2024 and $15,925 at 9/30/2025 .
- Board policy requires Audit Committee review/approval of related‑party transactions and Compensation Committee approval for executive compensation arrangements .
Risk Indicators & Red Flags
- Section 16 reporting timeliness: The company reports that Acevedo (and others) filed a Form 5 due to failure to file a Form 4 for transactions on December 5, 2024 .
- Policy gaps: As of the 2025 proxy, OSTX had not yet adopted formal insider trading or hedging policies; board intends to adopt in 2025 .
- Related‑party services: Ongoing use of CFO‑owned accounting firm for operational finance functions (payroll/bookkeeping/tax) reflects a potential conflict requiring oversight; payables outstanding to the firm were disclosed as above .
- Equity overhang/vesting: Executive ISO options vest over 3 years and had not vested (fair value $0) as of 12/31/2024, implying potential future vesting‑related liquidity windows rather than immediate selling pressure .
Investment Implications
- Pay-for-performance alignment: Cash compensation is minimal (part‑time role; $36k base) and bonuses were $0 in 2023–2024, with incentives concentrated in equity (options and share awards); however, OSTX disclosed no explicit financial/TSR metrics for NEO payouts in 2024, limiting line‑of‑sight pay-for-performance linkage at this stage .
- Retention and CoC economics: Severance is modest (12 months base plus prorated 35% of annual base) and there are no change‑of‑control provisions—lowering golden‑parachute risk but potentially reducing retention stickiness in strategic scenarios; restrictive covenants provide some post‑termination protection .
- Alignment and ownership: Acevedo’s reported beneficial ownership is <1% (109,375 shares as of Aug 20, 2025) versus 31.6M common shares outstanding, suggesting limited direct equity alignment by percentage, with additional unvested ISO options providing future upside .
- Governance and trading signals: The absence (as of the filing) of formal insider trading/hedging policies, a late Section 16 report (Form 5), and continued related‑party use of the CFO‑owned accounting firm require ongoing monitoring by investors for governance risk and potential trading activity once options begin to vest .
Appendix: Key Disclosures Cited
- SOX certifications and CFO role: Q3’25 10‑Q Exhibits 31.2 and 32 ; Q2’25 10‑Q signature page .
- Compensation summary (SCT) and philosophy: 2025 DEF 14A .
- Employment letter terms (salary/bonus/equity/severance/restrictive covenants; no CoC): 2025 DEF 14A and PRE 14A .
- Ownership table (as of 8/20/2025): 2025 DEF 14A .
- Related‑party fees (Shore Accountants MD Inc.): 2025 DEF 14A and Q3’25 10‑Q .
- Policy gaps (insider trading/hedging): 2025 DEF 14A .
- Section 16 timeliness: 2025 DEF 14A and PRE 14A .
- Make‑whole shares: Q3’25 10‑Q (Note on make‑whole share liability and issuance) .